NVS•benzinga•
FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool
Summary
FDA approves Novartis' Pluvicto for advanced prostate cancer patients who have received ARPI therapy.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 28, 2025 by benzinga